Summary
Abbott Laboratories (ABT) filed an 8-K on March 22, 2017, detailing the completion of its offers to exchange existing senior notes issued by St. Jude Medical, LLC (STJ) for new senior notes issued by Abbott. This transaction effectively consolidated STJ's debt under Abbott's corporate structure following the acquisition. The company successfully exchanged a significant principal amount of STJ's existing notes across various maturity dates and interest rates. As a result, a substantial portion of STJ's debt has been retired, with only a remaining principal amount of approximately $194 million across all five series of existing notes outstanding. The exchange offers and related consent solicitations to amend the indentures governing the existing notes have become effective.
Key Highlights
- 1Abbott Laboratories completed offers to exchange St. Jude Medical (STJ) existing senior notes for new Abbott senior notes.
- 2The exchange offers were coupled with a solicitation of consents to amend the indentures of the STJ notes.
- 3A significant aggregate principal amount of STJ's existing notes, across five series with maturities ranging from 2018 to 2043, were validly tendered and accepted.
- 4Following the exchange and cancellation, approximately $194.2 million of STJ's existing notes remain outstanding.
- 5Abbott issued new senior notes totaling approximately $2.8 billion to facilitate the exchange.
- 6The amendments to the indentures governing the STJ notes became effective on March 22, 2017.
- 7This action consolidates STJ's debt obligations under Abbott's corporate structure.